Lowest Price Guaranteed From USD 4,799
Published
January 2022
Pages
310
View Count
5270
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The cell and gene therapy bioassay services market is estimated to be worth around $155 million and is expected to grow at compounded annual growth rate (CAGR) of 30.1% during the forecast period. Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report’s publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages. Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services. Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.
The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays. In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.
The “Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of cell and gene therapy bioassay services market. We have provided an informed estimate of the evolution of the market for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell and gene therapy bioassay services market and its likely evolution in the short to mid-term and long term.
Chapter 3 provides a general introduction to bioassays and type of cell and gene therapy bioassays. It also highlights the importance of bioassay and challenges related to cell and gene therapy bioassays. Additionally, it provides a brief introduction to the concept of CROs, featuring a discussion on the role of contract service providers and prevalent outsourcing trends.
Chapter 4 provides a detailed assessment of the overall market landscape of cell and gene therapy bioassay service providers, including information on close to 50 stakeholders and a detailed analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of bioassay(s) offered (in vitro and in vivo), type of offerings (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).
Chapter 5 features an insightful competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, based on service strength (in terms of number of offering(s) of bioassays and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).
Chapter 6 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America. Each profile includes an overview of the company, financial (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, type of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.
Chapter 7 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.
Chapter 8 includes a contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and type of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers.
Chapter 9 includes a detailed analysis of the global events and strategic initiatives taken by the several cell and gene therapy bioassay service providers related to bioassays. The chapter features distribution of events on the basis of year of event, type of event, type of services involved and application area.
Chapter 10 is a case study of the overall landscape of cell and gene therapy therapeutics market, based on number of relevant parameters, such as phase of development, therapeutic area and type of developer, while highlighting key developers. The chapter also features information on the companies involved in the development of cell and gene therapies.
Chapter 11 features an in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
Chapter 12 features an in-depth analysis of more than 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the cell and gene therapy services market for the time period 2021-2030. In order to provide details on the future outlook, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the cell and gene therapy bioassay services market.
Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market.
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Bioassays
3.3. Cell and Gene Therapy Bioassays
3.4. Importance of Bioassays in Cell and Gene Therapy
3.5. Challenges Related to Cell and Gene Therapy Bioassays
3.6. Role of Contract Service Providers and Prevalent Outsourcing Trends
3.7. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Gene Therapy Bioassay Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Location of Bioanalytical Facilities
4.2.6. Analysis by Type of Bioassay(s) Offered
4.2.7. Analysis by Types of Offering(s) of Bioassay
4.2.8. Analysis of Type of Bioanalytical Service(s) Offered
4.2.9. Analysis by Application Area
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in North America
5.5. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in Europe and Asia-Pacific
6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. CCRM
6.2.1. Company Overview
6.2.2. Cell and Gene Therapy Bioassay Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Nexelis
6.3.1. Company Overview
6.3.2. Cell and Gene Therapy Bioassay Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Pacific BioLabs
6.4.1. Company Overview
6.4.2. Cell and Gene Therapy Bioassay Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PPD Laboratories
6.5.1. Company Overview
6.5.2. Cell and Gene Therapy Bioassay Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Cell and Gene Therapy Bioassay Service Portfolio
6.6.3. Recent Developments and Future Outlook
7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. AnaBioTec
7.2.1. Company Overview
7.2.2. Cell and Gene Therapy Bioassay Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Intertek Pharmaceutical Services
7.3.1. Company Overview
7.3.2. Cell and Gene Therapy Bioassay Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Lonza
7.4.1. Company Overview
7.4.2. Cell and Gene Therapy Bioassay Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Porton Bio
7.5.1. Company Overview
7.5.2. Cell and Gene Therapy Bioassay Service Portfolio
7.5.3. Recent Developments and Future Outlook
8. MARKET TREND ANALYSIS
8.1. Chapter Overview
8.2 Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioanalytical Service(s) Offered and Application Area
8.3. Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
8.4 Cell and Gene Therapy Bioassay Service Providers: Analysis by Location of Bioanalytical facilities
8.4.1. Players with Bioanalytical Facilities in US
8.4.2. Players with Bioanalytical Facilities in Rest of the World
9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS
9.1. Chapter Overview
9.2. Cell and Gene Therapy Bioassay Service Providers: List of Event and Strategic Initiatives
9.2.1. Analysis by Year of Event
9.2.2. Analysis by Type of Event
9.2.3. Analysis by Year and Type of Event
9.2.4. Analysis by Type of Services Involved
9.2.5. Analysis by Application Area
9.2.6. Prominent Players: Analysis by Number of Events and Strategic Initiatives
10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES
10.1. Chapter Overview
10.2. Cell Therapy Market
10.2.1. T-Cell Immunotherapies: Development Pipeline
10.2.1.1. Analysis by Type of Product
10.2.2. CAR-T Cell Therapies: Development Pipeline
10.2.2.1. Analysis by Phase of Development
10.2.2.2. Analysis by Therapeutic Area
10.2.2.3. Analysis by Type of Developer
10.2.2.4. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
10.2.3. TCR-based Therapies: Development Pipeline
10.2.3.1. Analysis by Phase of Development
10.2.3.2. Analysis by Therapeutic Area
10.2.3.3. Analysis by Type of Developer
10.2.3.4. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
10.2.4. TIL-based Therapies: Development Pipeline
10.2.4.1. Analysis by Phase of Development
10.2.4.2. Analysis by Therapeutic Area
10.2.4.3. Analysis by Type of Developer
10.2.4.4. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
10.3. Gene Therapy Market
10.3.1. Gene Therapy Market: Clinical and Commercial Pipeline
10.3.1.1. Analysis by Phase of Development
10.3.1.2. Analysis by Therapeutic Area
10.3.2. Gene Therapy Market: Development Pipeline
10.3.2.1. Analysis by Phase of Development
10.3.2.2. Analysis by Therapeutic Area
11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Potential Strategic Partners for Cell Therapy Bioassay Service Providers
11.3.1. Likely Partner Opportunities for Stem Cell Therapy Bioassay Service Providers
11.3.2. Likely Partner Opportunities for CAR-T Therapy Bioassay Service Providers
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy Bioassay Service Providers
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy Bioassay Service Providers
11.3.5. Likely Partner Opportunities for NK Cell Therapy Bioassay Service Providers
12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Gene Therapy Bioassay Service Providers
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Cell and Gene Therapy Bioassay Services Market
13.3.1. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Therapy
13.3.2. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Therapeutic Area
13.3.3. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Scale of Operation
13.3.4. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Geography
13.4. Cell Therapy Bioassay Services Market in North America, 2021-2030
13.4.1. Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.4.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.4.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.4.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.4.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.4.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.4.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.4.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.4.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.4.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.4.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.4.2. Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.4.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.4.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.4.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030
13.5. Cell Therapy Bioassay Services Market in Europe, 2021-2030
13.5.1. Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.5.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.5.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.5.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.5.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.5.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.5.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.5.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.5.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.5.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.5.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.5.2. Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.5.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.5.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.5.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030
13.6. Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.6.1. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.6.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.6.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.6.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.6.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.6.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.6.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.6.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.6.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.6.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.6.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.6.2. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.6.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.6.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.6.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030
13.7. Cell Therapy Bioassay Services Market in Latin America, 2021-2030
13.7.1. Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.7.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.7.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.7.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.7.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.7.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.7.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.7.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.7.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.7.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.7.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.7.2. Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.7.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.7.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.7.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030
13.8. Cell Therapy Bioassay Services Market in MENA, 2021-2030
13.8.1. Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.8.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.8.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.8.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.8.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.8.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.8.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.8.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.8.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.8.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.8.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.8.2. Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.8.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.8.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.8.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030
13.9. Gene Therapy Bioassay Services Market in North America, 2021-2030
13.9.1. Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.9.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.9.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.9.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.9.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.9.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.9.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.9.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.9.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.9.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.9.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.9.2. Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.9.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.9.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.9.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030
13.10. Gene Therapy Bioassay Services Market in Europe, 2021-2030
13.10.1. Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.10.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.10.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.10.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.10.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.10.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.10.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.10.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.10.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.10.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.10.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.10.2. Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.10.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.10.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.10.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030
13.11. Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.11.1. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.11.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.11.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.11.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.11.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.11.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.11.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.11.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.11.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.11.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.11.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.11.2. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.11.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.11.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.11.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030
13.12. Gene Therapy Bioassay Services Market in Latin America, 2021-2030
13.12.1. Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.12.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.12.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.12.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.12.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.12.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.12.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.12.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.12.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.12.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.12.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.12.2. Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.12.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.12.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.12.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030
13.13. Gene Therapy Bioassay Services Market in MENA, 2021-2030
13.13.1. Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.13.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.13.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.13.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.13.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.13.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.13.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.13.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.13.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.13.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.13.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.13.2. Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.13.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.13.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.13.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030
14. CONCLUSION
14.1. Chapter Overview
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Current Market Landscape of Cell and Gene Therapy Bioassay Service providers
Figure 2.2 Executive Summary: Clinical / Preclinical Pipeline of Cell and Gene Therapies
Figure 2.3 Executive Summary: Global Event and Strategic Analysis
Figure 2.4 Executive Summary: Market and Opportunity Analysis
Figure 3.1 Types of Cell and Gene Therapy Bioassays
Figure 4.1 Cell and Gene Therapy Bioassay Service Providers: Distribution by Year of Establishment
Figure 4.2 Cell and Gene Therapy Bioassay Service Providers: Distribution by Company Size
Figure 4.3 Cell and Gene Therapy Bioassay Service Providers: Distribution by Location of Headquarters
Figure 4.4 Cell and Gene Therapy Bioassay Service Providers: Distribution by Location of Bioanalytical Facilities
Figure 4.5 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) Offered
Figure 4.6 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Offering(s)
Figure 4.7 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered
Figure 4.8 Cell and Gene Therapy Bioassay Service Providers: Distribution by Application Area(s)
Figure 5.5 Company Competitiveness Analysis: Cell and Gene Therapy Service Providers in North America
Figure 5.6 Company Competitiveness Analysis: Cell and Gene Therapy Service Providers in Europe and Asia-Pacific
Figure 8.1 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered and Application Area
Figure 8.2 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
Figure 8.3 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in the US
Figure 8.4 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in Rest of the World
Figure 9.1 Global Events and Strategic Initiatives: Distribution by Year of Event, 2017-2021 (till September)
Figure 9.2 Global Events and Strategic Initiatives: Distribution by Types of Events, 2017-2021 (till September)
Figure 9.3 Global Events and Strategic Initiatives: Distribution by Year and Types of Events, 2017-2021 (till September)
Figure 9.4 Global Events and Strategic Initiatives: Distribution by Types of Services Involved, 2017-2021 (till September)
Figure 9.5 Global Events and Strategic Initiatives: Distribution by Application Area, 2017-2021 (till September)
Figure 9.6 Global Events and Strategic Initiatives: Distribution by Prominent Players, 2017-2021 (till September)
Figure 10.1 T-Cell Immunotherapies: Type of Product
Figure 10.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 10.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 10.4 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 10.5 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.6 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.7 TCR-based Therapies: Distribution by Phase of Development
Figure 10.8 TCR-based Therapies: Distribution by Therapeutic Area
Figure 10.9 TCR-based Therapies: Distribution by Type of Developer
Figure 10.10 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.11 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.12 TIL-based Therapies: Distribution by Phase of Development
Figure 10.13 TCR-based Therapies: Distribution by Therapeutic Area
Figure 10.14 TIL-based Therapies: Distribution by Type of Developer
Figure 10.15 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.16 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.17 Gene Therapies: Distribution by Phase of Development
Figure 10.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development
Figure 10.19 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 10.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 10.21 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development
Figure 10.22 Early Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 10.23 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 13.1 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030 (USD Million)
Figure 13.2 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Type of Therapy (USD Million)
Figure 13.3 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 13.4 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 13.5 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Geography (USD Million)
Figure 13.6 Cell Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Figure 13.7 Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.8 Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 13.9 Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Figure 13.10 Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Figure 13.11 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Figure 13.12 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 13.13 Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Figure 13.14 Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Figure 13.15 Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 13.16 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Figure 13.17 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 13.18 Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.19 Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Figure 13.20 Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 13.21 Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 13.22 Cell Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Figure 13.23 Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.24 Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.25 Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Figure 13.26 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Figure 13.27 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.28 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 13.29 Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.30 Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Figure 13.31 Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.32 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.33 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 13.34 Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.35 Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Figure 13.36 Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.37 Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.38 Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.39 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.40 Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.41 Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.42 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.43 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.44 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.45 Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.46 Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.47 Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.48 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.49 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.50 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.51 Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.52 Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.53 Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.54 Cell Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Figure 13.55 Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.56 Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.57 Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Figure 13.58 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.59 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.60 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.61 Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.62 Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.63 Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.64 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.65 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Figure 13.66 Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.67 Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Figure 13.68 Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.69 Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.70 Cell Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Figure 13.71 Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.72 Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.73 Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Figure 13.74 Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Figure 13.75 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.76 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Figure 13.77 Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.78 Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Figure 13.79 Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.80 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.81 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Figure 13.82 Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.83 Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Figure 13.84 Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.85 Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.86 Gene Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Figure 13.87 Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.88 Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 13.89 Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Figure 13.90 Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Figure 13.91 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Figure 13.92 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 13.93 Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Figure 13.94 Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Figure 13.95 Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 13.96 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Figure 13.97 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 13.98 Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.99 Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Figure 13.100 Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 13.101 Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 13.102 Gene Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Figure 13.103 Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.104 Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.105 Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Figure 13.106 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Figure 13.107 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.108 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 13.109 Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.110 Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Figure 13.111 Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.112 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.113 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.114 Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.115 Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Figure 13.116 Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.117 Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.118 Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.119 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.120 Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.121 Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.122 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.123 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.124 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.125 Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.126 Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.127 Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.128 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.129 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.130 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.131 Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.132 Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.133 Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.134 Gene Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Figure 13.135 Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.136 Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.137 Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Figure 13.138 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.139 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.140 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.141 Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.142 Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.143 Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.144 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.145 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Figure 13.146 Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.147 Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Figure 13.148 Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.149 Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.150 Gene Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Figure 13.151 Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.152 Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.153 Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Figure 13.154 Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Figure 13.155 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.156 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Figure 13.157 Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.158 Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Figure 13.159 Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.160 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.161 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Figure 13.162 Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.163 Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Figure 13.164 Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.165 Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Figure 14.1 Concluding Remarks: Current Market Landscape of Cell and Gene Therapy Bioassay Service providers
Figure 14.2 Concluding Remarks: Global Event and Strategic Analysis
Figure 14.3 Concluding Remarks: Clinical / Preclinical Pipeline of Cell and Gene Therapies
Figure 14.4 Concluding Remarks: Market and Opportunity Analysis
Table 3.1 List of Approved ATMP Products
Table 4.1 Cell and Gene Therapy Bioassay Services Market: List of Companies
Table 4.2 Cell and Gene Therapy Bioassay Services Market: Information on Type of Bioassay(s) Offered
Table 4.3 Cell and Gene Therapy Bioassay Services Market: Information on Type of Offering(s)
Table 4.4 Cell and Gene Therapy Bioassay Services Market: Information on Type of Bioanalytical Service(s) Offered
Table 4.5 Cell and Gene Therapy Bioassay Services Market: Information on Type of Application Area(s)
Table 6.1 Cell and Gene Therapy Bioassay Service Providers in North America: List of Companies Profiled
Table 6.2 CCRM: Company Snapshot
Table 6.3 CCRM: Cell and Gene Therapy Bioassay Services Offered
Table 6.4 CCRM: Recent Developments and Future Outlook
Table 6.5 Nexelis: Company Snapshot
Table 6.6 Nexelis: Cell and Gene Therapy Bioassay Services Offered
Table 6.7 Nexelis: Recent Developments and Future Outlook
Table 6.8 Pacific BioLabs: Company Snapshot
Table 6.9 Pacific BioLabs: Cell and Gene Therapy Bioassay Services Offered
Table 6.10 Pacific BioLabs: Recent Developments and Future Outlook
Table 6.11 PPD Laboratories: Company Snapshot
Table 6.12 PPD Laboratories: Cell and Gene Therapy Bioassay Services Offered
Table 6.13 PPD Laboratories: Recent Developments and Future Outlook
Table 6.14 WuXi Advanced Therapies: Company Snapshot
Table 6.15 WuXi Advanced Therapies: Cell and Gene Therapy Bioassay Services Offered
Table 6.16 WuXi Advanced Therapies: Recent Developments and Future Outlook
Table 7.1 Cell and Gene Therapy Bioassay Service Providers in Europe and Asia-Pacific: List of Companies Profiled
Table 7.2 AnaBioTec: Company Snapshot
Table 7.3 AnaBioTec: Cell and Gene Therapy Bioassay Services Offered
Table 7.4 AnaBioTec: Recent Developments and Future Outlook
Table 7.5 Intertek Pharmaceutical Services: Company Snapshot
Table 7.6 Intertek Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.7 Intertek Pharmaceutical Services: Cell and Gene Therapy Bioassay Services Offered
Table 7.8 Lonza: Company Snapshot
Table 7.9 Lonza: Cell and Gene Therapy Bioassay Service Portfolio
Table 7.10 Lonza: Recent Developments and Future Outlook
Table 7.11 Porton Bio: Company Snapshot
Table 7.12 Porton Bio: Cell and Gene Therapy Bioassay Services Offered
Table 7.13 Porton Bio: Recent Developments and Future Outlook
Table 9.1 Cell and Gene Therapy Bioassay Service Providers: List of Events and Strategic Initiatives
Table 10.1 CAR-T Cell Therapies: Clinical Pipeline
Table 10.2 CAR-T Cell Therapies: Preclinical Pipeline
Table 10.3 TCR-based Therapies: Clinical Pipeline
Table 10.4 TCR-based Therapies: Information on Sponsor, Type of Developer, Target Antigen, Target Indication and Therapeutic Area
Table 10.5 TIL-based Therapies: Clinical Pipeline
Table 10.6 TIL-based Therapies: Preclinical Pipeline
Table 10.7 Gene Therapy Market: Clinical and Commercial Pipeline
Table 10.8 Gene Therapy Market: Early Stage Pipeline
Table 11.1 Likely Partners for CAR-T Therapy Bioassay Service Providers
Table 11.2 Likely Partners for Stem Cell Therapy Bioassay Service Providers
Table 11.3 Likely Partners for Dendritic Cell Therapy Bioassay Service Providers
Table 11.4 Likely Partners for NK Cell Therapy Bioassay Service Providers
Table 11.5 Likely Partners for Tumor Cell Therapy Bioassay Service Providers
Table 12.1 Likely Partners for Gene Therapy Bioassay Service Providers in North America
Table 12.2 Likely Partners for Gene Therapy Bioassay Service Providers in Europe
Table 12.3 Likely Partners for Gene Therapy Bioassay Service Providers in Asia-Pacific
Table 16.1 Cell and Gene Therapy Bioassay Services Market: Distribution by Year of Establishment
Table 16.2 Cell and Gene Therapy Bioassay Services Market: Distribution by Company Size
Table 16.3 Cell and Gene Therapy Bioassay Services Market: Distribution by Location of Headquarters
Table 16.4 Cell and Gene Therapy Bioassay Services Market: Distribution by Location of Bioanalytical Facilities
Table 16.5 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Bioassay(s) Offered
Table 16.6 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Offering(s)
Table 16.7 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Bioanalytical Service(s) Offered
Table 16.8 Cell and Gene Therapy Bioassay Services Market: Distribution by Application Area(s)
Table 16.9 Company Competitiveness Analysis: Bioassay Service Providers for Cell and Gene Therapies in North America
Table 16.10 Company Competitiveness Analysis: Bioassay Service Providers for Cell and Gene Therapies in Europe and Asia-Pacific
Table 16.11 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered and Application Area
Table 16.12 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
Table 16.13 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in the US
Table 16.14 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in Rest of the World
Table 16.15 T-Cell Immunotherapies: Type of Product
Table 16.16 CAR-T Cell Therapies: Distribution by Phase of Development
Table 16.17 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 16.18 CAR-T Cell Therapies: Distribution by Type of Developer
Table 16.19 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.20 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.21 TCR-based Therapies: Distribution by Phase of Development
Table 16.22 TCR-based Therapies: Distribution by Therapeutic Area
Table 16.23 TCR-based Therapies: Distribution by Type of Developer
Table 16.24 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.25 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.26 TIL-based Therapies: Distribution by Phase of Development
Table 16.27 TCR-based Therapies: Distribution by Therapeutic Area
Table 16.28 TIL-based Therapies: Distribution by Type of Developer
Table 16.29 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.30 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.31 Gene Therapies: Distribution by Phase of Development
Table 16.32 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development
Table 15.33 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 16.34 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Table 16.35 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development
Table 16.36 Early Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 16.37 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Table 16.38 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030 (USD Million)
Table 16.39 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030: Distribution by Type of Therapy (USD Million)
Table 16.40 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 16.41 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Scale of Operation (USD Million)
Table 16.42 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Geography (USD Million)
Table 16.43 Cell Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Table 16.44 Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.45 Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 16.46 Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Table 16.47 Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Table 16.48 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Table 16.49 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 16.50 Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Table 16.51 Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Table 16.52 Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 16.53 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Table 16.54 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 16.55 Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.56 Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Table 16.57 Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 16.58 Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 16.59 Cell Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Table 16.60 Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.61 Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 16.62 Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Table 16.63 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Table 16.64 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Table 16.65 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 16.66 Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Table 16.67 Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Table 16.68 Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 16.69 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Table 16.70 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 16.71 Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.72 Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Table 16.73 Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 16.74 Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021 2030 (USD Million)
Table 16.75 Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Table 16.76 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.77 Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.78 Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Table 16.79 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.80 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.81 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.82 Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.83 Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.84 Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.85 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.86 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 16.87 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.88 Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.89 Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.90 Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.91 Cell Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Table 16.92 Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.93 Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.94 Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Table 16.95 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Table 16.96 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.97 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Table 16.98 Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.99 Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Table 16.100 Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.101 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.102 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Table 16.103 Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.104 Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Table 16.105 Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.106 Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.107 Cell Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Table 16.108 Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.109 Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Table 16.110 Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Table 16.111 Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Table 16.112 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Table 16.113 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Table 16.114 Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Table 16.115 Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Table 16.116 Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Table 16.117 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Table 16.118 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Table 16.119 Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.120 Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Table 16.121 Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Table 16.122 Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Table 16.123 Gene Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Table 16.124 Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.125 Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 16.126 Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Table 16.127 Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Table 16.128 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Table 16.129 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 16.130 Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Table 16.131 Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Table 16.132 Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 16.133 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Table 16.134 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 16.135 Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.136 Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Table 16.137 Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 16.138 Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 16.139 Gene Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Table 16.140 Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.141 Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 16.142 Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Table 16.143 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Table 16.144 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Table 16.145 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 16.146 Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Table 16.147 Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Table 16.148 Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 16.149 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Table 16.150 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 16.151 Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.152 Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Table 16.153 Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 16.154 Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 16.155 Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Table 16.156 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.157 Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.158 Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Table 16.159 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.160 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.161 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.162 Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.163 Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.164 Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.165 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.166 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 16.167 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.168 Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.169 Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.170 Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.171 Gene Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Table 16.172 Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.173 Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.174 Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Table 16.175 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Table 16.176 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.177 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Table 16.178 Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.179 Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Table 16.180 Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.181 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.182 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Table 16.183 Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.184 Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Table 16.185 Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.186 Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.187 Gene Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Table 16.188 Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.189 Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Table 16.190 Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Table 16.191 Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Table 16.192 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Table 16.193 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Table 16.194 Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Table 16.195 Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Table 16.196 Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Table 16.197 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Table 16.198 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Table 16.199 Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.200 Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Table 16.201 Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Table 16.202 Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES